Novo Nordisk Current Ratio 2006-2018 | NVO

Current and historical current ratio for Novo Nordisk (NVO) from 2006 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Novo Nordisk current ratio for the three months ending December 31, 2018 was 1.09.
Novo Nordisk Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-12-31 $9.03B $8.28B 1.09
2018-09-30 $8.45B $7.71B 1.10
2018-06-30 $9.21B $7.87B 1.17
2018-03-31 $8.24B $7.29B 1.13
2017-12-31 $9.13B $7.15B 1.28
2017-09-30 $9.02B $7.13B 1.27
2017-06-30 $8.72B $6.48B 1.35
2017-03-31 $7.98B $7.01B 1.14
2016-12-31 $8.88B $7.05B 1.26
2016-09-30 $7.74B $6.24B 1.24
2016-06-30 $7.99B $6.31B 1.27
2016-03-31 $6.86B $6.08B 1.13
2015-12-31 $8.21B $6.08B 1.35
2015-09-30 $7.68B $5.74B 1.34
2015-06-30 $7.02B $5.72B 1.23
2015-03-31 $6.59B $6.37B 1.04
2014-12-31 $8.25B $6.01B 1.37
2014-09-30 $7.33B $5.35B 1.37
2014-06-30 $6.29B $4.37B 1.44
2014-03-31 $6.34B $4.85B 1.31
2013-12-31 $7.49B $4.31B 1.74
2013-09-30 $7.27B $4.56B 1.59
2013-06-30 $6.40B $4.45B 1.44
2013-03-31 $6.34B $4.54B 1.40
2012-12-31 $6.94B $3.74B 1.86
2012-09-30 $6.87B $4.41B 1.56
2012-06-30 $6.21B $4.12B 1.51
2012-03-31 $6.41B $3.88B 1.65
2011-12-31 $7.40B $3.88B 1.91
2011-09-30 $7.37B $3.87B 1.91
2011-06-30 $7.31B $3.59B 2.04
2011-03-31 $6.51B $3.35B 1.94
2010-12-31 $6.65B $3.29B 2.02
2010-09-30 $5.87B $2.93B 2.00
2010-06-30 $5.78B $3.13B 1.85
2010-03-31 $5.84B $2.89B 2.02
2009-12-31 $6.12B $2.51B 2.44
2009-09-30 $5.95B $2.48B 2.40
2009-06-30 $5.44B $2.28B 2.38
2009-03-31 $5.02B $2.48B 2.03
2008-12-31 $5.73B $2.55B 2.24
2008-09-30 $5.48B $2.49B 2.20
2008-06-30 $5.51B $2.32B 2.38
2008-03-31 $4.98B $2.33B 2.13
2007-12-31 $4.47B $1.96B 2.28
2007-09-30 $4.30B $1.99B 2.16
2007-06-30 $4.15B $1.91B 2.17
2007-03-31 $3.68B $1.88B 1.97
2006-12-31 $3.50B $1.71B 2.05
2006-09-30 $3.51B $1.96B 1.79
2006-06-30 $3.41B $1.72B 1.99
2006-03-31 $3.04B $1.69B 1.80
2005-12-31 $3.27B $1.77B 1.85
2005-09-30 $2.94B $1.51B 1.95
2005-06-30 $2.72B $1.45B 1.87
2005-03-31 $2.84B $1.29B 2.19
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $117.534B $17.724B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $369.784B 16.77
Pfizer (PFE) United States $232.043B 12.99
Merck (MRK) United States $198.062B 16.93
Novartis AG (NVS) Switzerland $174.174B 14.81
Eli Lilly (LLY) United States $119.606B 20.77
AbbVie (ABBV) United States $115.278B 9.88
Sanofi (SNY) France $103.709B 12.80
GlaxoSmithKline (GSK) United Kingdom $98.430B 12.93
AstraZeneca (AZN) United Kingdom $98.150B 11.20
Bristol-Myers Squibb (BMY) United States $73.920B 11.37